Full-Time

Senior Manager Sterility Assurance

Posted on 6/6/2026

Viatris

Viatris

10,001+ employees

Global pharma selling generics and biosimilars

No salary listed

Minna, Inverin, Co. Galway, Ireland

In Person

Category
Biology & Biotech (1)
Required Skills
Microbiology
Requirements
  • A Bachelor’s degree in Microbiology or a closely related field (e.g., Biotechnology).
  • Extensive years of experience in sterility assurance, aseptic manufacturing, or a related field, with a strong emphasis on microbiology and contamination control.
Responsibilities
  • Lead the site Sterility Assurance strategy and program, ensuring compliance with EU GMP Annex 1 and global regulatory requirements.
  • Develop and maintain the Contamination Control Strategy to support sterile manufacturing operations.
  • Conduct risk assessments for aseptic processes, environmental monitoring, and container closure systems to mitigate contamination risks.
  • Oversee and continuously improve the environmental monitoring program to ensure robust contamination control.
  • Lead and support microbiological investigations, ensuring appropriate root cause analysis and effective CAPA implementation.
  • Coordinate and oversee aseptic process simulations (media fills) and support review and approval of related documentation.
  • Support validation and qualification activities related to sterility testing, aseptic processes, and laboratory systems.
  • Represent sterility assurance in internal and external audits and regulatory inspections, addressing observations and driving corrective actions.
  • Collaborate cross-functionally with Quality, Manufacturing, Engineering, and Microbiology teams to ensure alignment on sterility assurance practices.
  • Maintain and approve key sterility assurance documentation, including SOPs, validation protocols, and contamination control plans.
  • Monitor and report sterility assurance performance metrics and trends, driving continuous improvement across the site.

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Greater China and emerging markets drove Q1 2026 growth.
  • Six 2026 regulatory decisions can unlock multiple launches.
  • $650 million cost savings and $2.5 billion deployable cash support returns.

What critics are saying

  • North American generic pricing pressure keeps compressing core developed-market revenue.
  • Launch-dependent guidance fails if MR-107A-02 or MR-141 slips.
  • China concentration exposes growth to policy and channel disruptions.

What makes Viatris unique

  • Formed in November 2020 from Mylan and Upjohn.
  • Operates across more than 165 countries with 1,400 therapeutic molecules.
  • Combines branded, generic, complex, biosimilar, and OTC medicines.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Viatris who can refer or advise you

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-6%

2 year growth

-6%
Yahoo Finance
Mar 23rd, 2026
Viatris shares surge 39.8% over past year, outpacing health care sector by 38.7%

Viatris, a global pharmaceutical company with a $15.2 billion market cap, has outperformed the broader healthcare sector despite recent headwinds. The Pennsylvania-based firm, which operates across 120 countries, has gained 39.8% over the past year, substantially ahead of the State Street Health Care Select Sector SPDR Fund's 1.1% decline. Shares have risen 10.7% over three months and 33.3% over six months, though they remain 19.9% below their 52-week high of $16.47. Viatris reported fourth-quarter revenue of $3.7 billion, up 5% year over year, with adjusted earnings per share of $0.57. Strong performance in branded drugs and emerging markets was offset by restructuring charges and pricing pressure in generics. Shares fell 5.2% following the announcement.

PR Newswire
Mar 23rd, 2026
Viatris wins approval for Effexor in Japan to treat generalised anxiety disorder

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults, making it the first and only approved treatment for GAD in Japan. The drug was already approved in the country for major depressive disorder. The approval addresses a significant unmet need, as a recent study reported probable GAD prevalence of 7.6% in Japan's general population. The decision was based on a Phase 3 trial that demonstrated superior anxiolytic effects versus placebo at eight weeks, with all seven secondary endpoints met. Effexor was generally well tolerated with low discontinuation rates. Viatris' Japanese portfolio includes innovative products such as Spydia Nasal Spray, with several investigational therapies in development. Effexor is approved for GAD in over 80 countries worldwide.

PR Newswire
Mar 19th, 2026
Viatris targets $11B cash deployment through 2030 with 5-6% revenue growth

Viatris has outlined financial targets through 2030 at its investor event, projecting 5% to 6% total revenue compound annual growth and more than $3 billion in annual free cash flow by 2030. The pharmaceutical company's valuation at $1.45 billion reflects investor confidence in its strategic evolution. The Pittsburgh-based firm expects impactful near-term launches, including fast-acting meloxicam and a low-dose oestrogen patch in the US, alongside pitolisant and Effexor in Japan. Longer-term growth potential includes drug candidates selatogrel and cenerimod. Viatris anticipates over $11 billion in cash available for deployment through 2030, with approximately 50% allocated to business development. The company recently identified $650 million in cost savings over three years through an enterprise-wide strategic review.

Yahoo Finance
Mar 11th, 2026
Viatris shares surge 37.8% in six months, but analysts warn against buying despite cheap 5.8× P/E valuation

Viatris shares have surged 37.8% over the past six months, outpacing the S&P 500 by 34.7 percentage points, trading at $14.11. Despite the recent rally, analysts remain cautious about the pharmaceutical company's prospects. The company's fundamentals show concerning trends. Revenue grew at just 3.7% annually over the past five years, whilst earnings per share declined 9.8% annually during the same period, indicating deteriorating profitability. Most notably, Viatris posted a negative 2.6% five-year average return on invested capital, meaning management lost money whilst attempting business expansion. The stock currently trades at 5.8× forward price-to-earnings ratio. Analysts suggest the valuation appears optically cheap but warn of significant downside risk given the weak underlying fundamentals.

Yahoo Finance
Feb 26th, 2026
Viatris reports Q4 revenue of $3.7B, beating estimates by 5% with 10% growth in emerging markets

Viatris reported $3.7 billion in revenue for the quarter ended December 2025, representing a 5% year-over-year increase and beating the Zacks Consensus Estimate by 5.29%. Earnings per share reached $0.57, up from $0.54 a year ago and surpassing the consensus estimate of $0.52 by 9.62%. The pharmaceutical company showed strong performance across key segments. Greater China net sales rose 9.8% to $572.9 million, whilst Emerging Markets increased 10.1% to $564.7 million. Developed Markets generated $2.25 billion, up 4.7% year-over-year and exceeding analyst estimates. Shares of Viatris have gained 24% over the past month. The stock currently holds a Zacks Rank 3, suggesting it could perform in line with the broader market near term.